Overall survival in patients with metastatic melanoma

Current Medical Research and Opinion

Volumn 31, Issue 5, 2015, Pages 987-991

  Song, Xue ^a   Zhao, Zhongyun ^b   Barber, Beth ^b   Farr, Amanda M ^a   Ivanov, Boris ^a   Novich, Marilyn ^a  

^a IBM WATSON HEALTH   (United States)

^b AMGEN INC   (United States)

Author keywords

Disease stage; Metastatic melanoma; Overall survival

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; FEMALE; FOLLOW UP; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SURVIVAL RATE; CANCER REGISTRY; MELANOMA; METASTASIS; PATHOLOGY; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; SEER PROGRAM; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84928202737     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1021904     Document Type: Article

References (17)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute. Available at: http:// seer.cancer.gov/csr/1975-2010/ [Last accessed 5 March 2015]
2. National Comprehensive Cancer Network. NCCN Guidelines for Patients: Melanoma. Version 1, 2014. Available at: http://ww.nccn.org/patients/ guidelines/melanoma/files/assets/basic-html/index.html#1 [Last accessed 5 March 2015]
3. National Cancer Institute. NCI Cancer Drug Information: Drugs Approved for Melanoma. Available at: http://www.cancer.gov/cancertopics/druginfo/melanoma [Last accessed 5 March 2015]
4. National Cancer Institute. FDA Approval for Ipilimumab. Available at: http:// www.cancer.gov/cancertopics/druginfo/fda-ipilimumab [Last accessed 5 March 2015]
5. National Cancer Institute. FDA Approval for Vemurafenib. Available at: http://www.cancer.gov/cancertopics/druginfo/fda-vemurafenib [Last accessed 5 March 2015]
6. Surveillance, Epidemiology, and End Results. Available at: http://seer. cancer.gov/ [Last accessed 5 March 2015]
7. National Cancer Institute. SEER as a Research Resource. 2010. Available at: http://seer.cancer.gov/about/factsheets/SEER-Research-Brochure.pdf [Last accessed 5 March 2015]
8. National Cancer Institute. Data Flow in NCI's SEER Registries. 2011. Available at: http://seer.cancer.gov/about/factsheets/SEER-Data-Flow-.pdf [Last accessed 5 March 2015]
9. National Cancer Institute. SEER Program Coding and Staging Manual. 2013. Available at: http://seer.cancer.gov/manuals/2013/SPCSM-2013 maindoc.pdf [Last accessed 5 March 2015]
10. Surveillance, Epidemiology, and End Results (SEER) Program Research Data (1973-2009), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission. Available at: www.seer.cancer.gov [Last accessed 5 March 2015]
11. SEER Research Data Record Description Cases Diagnosed in 1973-2009. 2012. Available at: http://seer.cancer.gov/data/seerstat/nov2011/TextData. FileDescription.pdf [Last accessed 5 March 2015]
12. Surveillance, Epidemiology and End Results. SEER Stat Fact Sheets: Melanoma of the Skin. Available at: http://seer.cancer.gov/statfacts/html/melan.html [Last accessed 5 March 2015]
13. Lai SM, King JB, Garimella S, et al. Effect of the staging schema on melanoma cancer reporting, 1999 to 2006. J Am Acad Dermatol 2011;65(5 Suppl 1):S95-103
14. Pollack LA, Li J, Berkowitz Z, et al. Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol 2011;65(5 Suppl 1):S78-86
15. Xing Y, Chang GJ, Hu CY, et al. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 2010;116:2234-41
16. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48
17. Yu JB, Gross CP, Wilson LD, Smith BD. NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park) 2009;23:288-95